ECSP23057264A - Inhibidores de cdk2 y métodos de uso de los mismos - Google Patents

Inhibidores de cdk2 y métodos de uso de los mismos

Info

Publication number
ECSP23057264A
ECSP23057264A ECSENADI202357264A ECDI202357264A ECSP23057264A EC SP23057264 A ECSP23057264 A EC SP23057264A EC SENADI202357264 A ECSENADI202357264 A EC SENADI202357264A EC DI202357264 A ECDI202357264 A EC DI202357264A EC SP23057264 A ECSP23057264 A EC SP23057264A
Authority
EC
Ecuador
Prior art keywords
methods
cdk2
cdk2 inhibitors
inhibitors
disorders
Prior art date
Application number
ECSENADI202357264A
Other languages
English (en)
Inventor
Louise Clare Kirman
Carl Eric Schwartz
Thomas P Blaisdell
Dale A Porter
Wojtek Michowski
John Feutrill
John Paul Sherrill
Original Assignee
Cedilla Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedilla Therapeutics Inc filed Critical Cedilla Therapeutics Inc
Publication of ECSP23057264A publication Critical patent/ECSP23057264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos, composiciones de los mismos y métodos de uso de los mismos para la inhibición de CDK2, y el tratamiento de enfermedades y trastornos relacionados con CDK2.
ECSENADI202357264A 2021-01-29 2023-07-27 Inhibidores de cdk2 y métodos de uso de los mismos ECSP23057264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163143360P 2021-01-29 2021-01-29

Publications (1)

Publication Number Publication Date
ECSP23057264A true ECSP23057264A (es) 2023-09-29

Family

ID=82654899

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202357264A ECSP23057264A (es) 2021-01-29 2023-07-27 Inhibidores de cdk2 y métodos de uso de los mismos

Country Status (21)

Country Link
US (2) US12065445B2 (es)
EP (1) EP4284365A4 (es)
JP (1) JP2024505261A (es)
KR (1) KR20230142745A (es)
CN (1) CN117177744A (es)
AU (1) AU2022214618A1 (es)
BR (1) BR112023015210A2 (es)
CA (1) CA3208618A1 (es)
CL (1) CL2023002223A1 (es)
CO (1) CO2023010023A2 (es)
CR (1) CR20230362A (es)
DO (1) DOP2023000145A (es)
EC (1) ECSP23057264A (es)
GE (1) GEAP202316332A (es)
IL (1) IL304728A (es)
JO (1) JOP20230170A1 (es)
MX (1) MX2023008968A (es)
PE (1) PE20240050A1 (es)
PH (1) PH12023552079A1 (es)
TW (1) TW202239402A (es)
WO (1) WO2022165513A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022165513A1 (en) 2021-01-29 2022-08-04 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
US20260034123A1 (en) * 2022-07-28 2026-02-05 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3263003A1 (en) * 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
WO2024026479A2 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3263133A1 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
CN120659773A (zh) * 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
DE10360745A1 (de) 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CN1950082B (zh) 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
EP2298770A1 (en) 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CN101910165A (zh) * 2007-10-29 2010-12-08 先灵公司 作为蛋白质激酶抑制剂的噻唑衍生物
PA8802501A1 (es) 2007-10-31 2009-06-23 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
ES2462290T3 (es) 2009-06-08 2014-05-22 Grünenthal GmbH Bencimidazoles, benzotiazoles y benzoxazoles sustituidos
EP2473056A4 (en) * 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
UY33199A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
JP5699223B2 (ja) 2010-12-02 2015-04-08 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
CN102952118B (zh) 2011-08-17 2016-03-23 上海迪诺医药科技有限公司 聚（adp-核糖）聚合酶抑制剂、制备方法及其用途
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
WO2015048570A2 (en) 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Ebi2 modulators
US9920073B2 (en) 2013-10-04 2018-03-20 Drexel University Compositions useful for inhibiting HIV-1 infection and methods using same
RU2016141934A (ru) 2014-04-04 2018-05-07 Сирос Фармасьютикалз, Инк. Ингибиторы циклин-зависимой киназы 7 (cdk7)
JP6581111B2 (ja) 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
MX375153B (es) 2014-05-19 2025-03-06 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelminticos.
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN105461693B (zh) 2014-09-26 2019-10-25 广东东阳光药业有限公司 Crth2拮抗剂化合物及其用途
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
EP3512858B1 (en) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Fused bicyclic inhibitors of menin-mll interaction
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
ES2905164T3 (es) 2017-07-21 2022-04-07 Sichuan Haisco Pharmaceutical Co Ltd Compuesto de amida peptídico y método de preparación y uso médico del mismo
JP7177825B2 (ja) 2017-08-29 2022-11-24 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
CN111902386A (zh) 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 作为fto抑制剂的苯基甲酮衍生物
CN110156674A (zh) 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CA3129516A1 (en) * 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
WO2020086739A1 (en) 2018-10-24 2020-04-30 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
KR20210097734A (ko) 2018-11-28 2021-08-09 하. 룬드벡 아크티에셀스카브 Magl 저해제에 의해 질병을 치료하는 방법
KR20210097715A (ko) 2018-11-29 2021-08-09 아락세스 파마 엘엘씨 암 치료용 화합물 및 이의 사용 방법
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111138358B (zh) 2019-12-17 2023-04-18 中国药科大学 Usp8抑制剂及其制备方法与应用
WO2022165513A1 (en) 2021-01-29 2022-08-04 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
US20260034123A1 (en) 2022-07-28 2026-02-05 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3263003A1 (en) 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
WO2024026479A2 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026484A2 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3263133A1 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
BR112023015210A2 (pt) 2023-11-07
US20230109076A1 (en) 2023-04-06
GEAP202316332A (en) 2023-12-11
CN117177744A (zh) 2023-12-05
CO2023010023A2 (es) 2023-09-08
PH12023552079A1 (en) 2024-01-22
DOP2023000145A (es) 2023-10-31
MX2023008968A (es) 2023-09-22
PE20240050A1 (es) 2024-01-09
EP4284365A1 (en) 2023-12-06
US12065445B2 (en) 2024-08-20
KR20230142745A (ko) 2023-10-11
WO2022165513A1 (en) 2022-08-04
JOP20230170A1 (ar) 2023-07-27
US20240174680A1 (en) 2024-05-30
CA3208618A1 (en) 2022-08-04
JP2024505261A (ja) 2024-02-05
AU2022214618A1 (en) 2023-08-17
EP4284365A4 (en) 2024-12-18
CL2023002223A1 (es) 2023-12-29
IL304728A (en) 2023-09-01
TW202239402A (zh) 2022-10-16
CR20230362A (es) 2023-11-23

Similar Documents

Publication Publication Date Title
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CO2026004964A2 (es) Moduladores de kras
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
MX2021002804A (es) Terapias de combinacion.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
MX2024008551A (es) Terapias de combinacion.
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
BR112022003768A2 (pt) Compostos inibidores de perk
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
CO2022000266A2 (es) Inhibidores de enzimas
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
CO2024009144A2 (es) Inhibidores de cinasa met